Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could ozempic shield psoriatic arthritis patients from heart disease?

NCT ID NCT07251556

Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether semaglutide (Ozempic), a drug used for diabetes and weight loss, can slow the buildup of plaque in arteries of people with psoriatic arthritis who do not have diabetes. Forty participants will receive either semaglutide or no additional treatment for 24 weeks. Researchers will measure changes in carotid artery thickness and stiffness to see if the drug reduces heart disease risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide (Ozempic)
What this could lead to
If it works, this could point toward a new way to lower heart disease risk in people with psoriatic arthritis who do not have diabetes.
What could go wrong
This is a small, early proof-of-concept study with only 40 participants, so results may not apply widely. The drug can cause gastrointestinal side effects, and it is not yet known if it will meaningfully affect artery health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. fulfill the ClASsification criteria for Psoriatic Arthritis, 2. are rheumatoid factor negative, 3. BMI \>=25 kg/m2, 4. are over 18 years old and 5. Chinese subjects Exclusion Criteria: 1. have prior therapy with GLP-1 receptor agonists during the last 24 weeks, 2. have pre-existing diabetes, 3. have liver or renal impairment, 4. have known or symptoms suggestive of CVD, 5. have chronic or previous acute pancreatitis, 6. have current malignancy, 7. are pregnant, breastfeeding or of childbearing potential, or 8. are unable to give written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis arthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.